Patent intelligence · US
US 12240833
Pyridazinone compounds and uses thereof
Pyridazinone compounds and uses thereof
Patent details — US 12240833
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 4, 2025
- Expiration
- Feb 27, 2045
- Applicant
- EDGEWISE THERAPEUTICS, INC.
- Claims
- 28
- CPC classes
- A61P, A61P21/00
Quick answer
US 12240833 (Pyridazinone compounds and uses thereof) is held by EDGEWISE THERAPEUTICS, INC.. Status: granted. Granted Mar 4, 2025. Expires Feb 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- EDGEWISE THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61P, A61P21/00
More from EDGEWISE THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12415794
Pyridazinone compounds and uses thereof
granted -
US 12240831
Pyridazinone compounds and uses thereof
granted -
US 12012395
Pyridazinone compounds and uses thereof
granted -
US 11390606
Pyridazinone compounds and uses thereof
granted -
US 11236065
Pyridazinone compounds and uses thereof
granted -
US 11091464
Pyridazinone compounds and uses thereof
granted
Frequently asked questions
What is US patent 12240833?
US 12240833 (Pyridazinone compounds and uses thereof) is held by EDGEWISE THERAPEUTICS, INC.. Status: granted. Granted Mar 4, 2025. Expires Feb 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12240833?
EDGEWISE THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 12240833 expire?
Our index shows an expiration date of Feb 27, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.